AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04508426
Drug: [14C]AR882
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of \[14C\]AR882
Trial: NCT03437746
Drug: injection of methylprednisolone at anesthetic induction
RxNorm normalized name: methylprednisolone Injection
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous administration : 20 mg/kg, over 30 minutes at anesthetic induction
Trial: NCT00869037
Drug: CFNB + Posterior Capsular Injection
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 20 ml bolus of 0.2% Ropivacaine will be given via a femoral nerve catheter. Periarticular infiltration will be performed intra-op. 20 ml of 1% Ropivacaine in the posterior capsule; 20 ml of normal saline in the quadriceps mechanism, retinacular tissues, medial and lateral collateral ligaments; 20 ml of normal saline for the skin and subcutaneous tissues. Postoperatively, the femoral catheter will be infused with 0.15% Ropivacaine running at 15 ml/hour until the morning of post-operative day 2
Trial: NCT00744640
Drug: gemcitabine, oxaliplatin, capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemcitabine day 1 and 8, oxaliplatin day 1, capecitabine days 1-14, q3weeks
Trial: NCT03696004
Drug: FEC-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will recieve six cycles of FEC-100 and Breast conservative surgery after 4-6 weeks
Trial: NCT01770886
Drug: UE2343
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT01770886
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT02927184
Drug: VK2809
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02927184
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03674541
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Cellulose microcrystalline) capsule by mouth as a one time dose
Trial: NCT03169114
Drug: Amikacin Injection
RxNorm normalized name: amikacin Injection
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants allocated to Antibiotic Non-operative Management Strategy will be given intravenous Amikacin 15mg/kg/day divided over 3 doses for first 48 hours and followed by oral ciprofloxacin 500mg bd for 7 days
Trial: NCT02795650
Drug: Personalised treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalised treatments include chemotherapy, targeted therapy, immunotherapy or others based on the previous test results, chosen from a database that include more than 2000 different drugs.
Trial: NCT02795650
Drug: Treatment chosen per investigator´s judge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigators are allowed to chose what they consider the best standard treatment option for their patients.
Trial: NCT00002995
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02562716
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04314986
Drug: Cohort 1: AR882 or placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AR882 or matching placebo administered once daily for 10 days
Trial: NCT04314986
Drug: Cohort 2: AR882 or placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AR882 or matching placebo administered once daily for 10 days.
Trial: NCT04314986
Drug: Cohort 3: AR882 or placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AR882 or matching placebo administered once daily for 10 days
Trial: NCT04314986
Drug: Cohort 4: AR882 or placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AR882 or matching placebo administered once daily for 10 days
Trial: NCT04365400
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules
Trial: NCT00480766
Drug: MK0217/Duration of Treatment : 12 Months
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03122652
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet once a day
Trial: NCT03030417
Drug: LMP744
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indenoisoquinolines, such as LMP744, are potent inhibitors of the enzyme topoisomerase I (Top1). Top1 is necessary for transcription, replication, recombination, and the repair of double-strand deoxyribonucleic acid (DNA) breaks. It relaxes the supercoiled DNA by introducing a single-strand break, generating a free strand that rotates around the Top1-bound DNA complex. In the absence of external triggers, Top1-DNA cleavage complexes are generally short lived. Top1 inhibitors are potent anticancer agents because they stabilize the formation of the Top1-DNA cleavage complex in tumor cells, which induces DNA damage, delays DNA repair, and results in cell cycle arrest and apoptosis. LMP744 exhibited antitumor activity with lower toxicity than other agents in preclinical studies. Treatment of patients with LMP744 is expected to reduce tumor burden at doses that are well-tolerated.
Trial: NCT01335932
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For first 5 days, dosing of intravenous placebo is daily, given every 12 hours. After first 5 days (up to 28 days), IV placebo QD. A minimum interval of 6 hours is required between the first and second dose.~The placebo is an IV solution that does not contain any active medications.
Trial: NCT01909336
Drug: 0.3% Saline in 3.3% dextrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypotonic Solutions: 0.3% Saline in 3.3% dextrose
Trial: NCT01909336
Drug: 0.45% Saline in 5% dextrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypotonic Solutions: 0.45% Saline in 5% dextrose
Trial: NCT01909336
Drug: 0.9% Saline in 5% dextrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic Solutions 0.9% Saline in 5% dextrose
Trial: NCT04189107
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low dose dexamethasone peroperative and placebo postoperatively on day 2 and 4
Trial: NCT03108300
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin is a chemotherapy which will be injected by a dose 60 mg per meter square of body surface area to be repeated every 21days
Trial: NCT01853852
Drug: GR181413A/AT1001 solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powder for reconstitution
Trial: NCT01853852
Drug: GR181413A/AT1001 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Size 2, hard gelatin capsule, white opaque / blue opaque
Trial: NCT01853852
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution matched
Trial: NCT00002819
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00533351
Drug: AGN201781
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGN201781 50 mg capsules three-times daily for 2 weeks
Trial: NCT00533351
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 50 mg capsules three-times daily for 2 weeks
Trial: NCT04509557
Drug: [177Lu]Ludotadipep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose is sequentially elevated starting from a low dose to a high dose (50±5 mCi, 75±8 mCi, 100±10 mCi, 125±13 mCi, 150±15 mCi). If DLT is observed in 2 or less of 6 subjects at each level, advance to the next step. If DLT is observed in 3 or more participants, no further subject will participate in the study at the relevant dose. Appropriateness of the dose elevation is evaluated 8-9 weeks after drug administration.
Trial: NCT03758950
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily inhaled placebo for 48 weeks
Trial: NCT00597519
Drug: Fludarabine, Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine 25 mg/m2/day IV in the morning x 3 days (days -7, -6 and -5) for a total dose of 75 mg/m2 followed by Cyclophosphamide on days -6 and -5. 60mg/kg/day IV over 30-60 minutes x 2 days (days -6 and -5). High volume fluids should commence approximately 12 hours prior to drug and continue until 24 hours after second dose.~Total Body Irradiation: 125 cGy x 11 doses (TID on days -3, -2, -1 and BID on day 0) for a total TBI dose of 1375 cGy. Pediatric patients unable to tolerate a TID dosing schedule can receive 150 cGy x 8 doses (BID on days -3, -2, -1, and 0). All patients will receive GVHD prophylaxis with 2 drugs: Cyclosporine A and Mycophenolate mofetil (MMF).~Units should be given consecutively each over approximately 10-30 minutes.Pre-medication should include acetaminophen and diphenhydramine or hydroxyzine.G-CSF 5 mcg/kg/day IV/SQ (dose rounded to vial size to a maximum of 480 mcg) will be given from day +1 until ANC recovery.
Trial: NCT00628342
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral once daily
Trial: NCT02955498
Drug: Sevikar tab. 10/40mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference drug: Sevikar tab. 10/40mg, 1T, single oral administration in the fasted state
Trial: NCT02955498
Drug: Lodivikar tab. 5/40mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test drug: Lodivikar tab 5/40mg, 1T, single oral administration in the fasted state
Trial: NCT01301469
Drug: 6% HES 130/0.4 in a saline solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 g/l Hydroxyethyl starch (HES) with a mean molecular weight of 130 kDalton which is dissolved in a saline solution
Trial: NCT04286529
Drug: Oral Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be created to mimic the appearance of the study drug
Trial: NCT00587678
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mg each night
Trial: NCT00587678
Drug: Simvastatin/Ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mg/10mg each night
Trial: NCT01444885
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 weeks treatment of Cilostazol 100mg, or placebo oral tablets bid after 2 weeks treatment of Cilostazol 50mg, or placebo oral tablets bid (Total 4 weeks)
Trial: NCT00821496
Drug: ethinyl estradiol, norethindrone, VI-0521
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive
Trial: NCT00104650
Drug: IV Bisphosphonate q 4 weeks
RxNorm normalized name: Q
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Bisphosphonate (eg pamidronate or zoledronic acid) every 4 weeks for 6 doses as described by package insert during the treatment phase. If enrolled to the extension phase, subject will be assigned to the AMG 162 180mg (SC) every 4 weeks for 26 doses.
Trial: NCT00982826
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See Arms information for a detailed description.
Trial: NCT01643382
Drug: Insulin, Asp(B28)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin will be given through subcutaneous injection every few hours based on the patient's blood sugar level.
Trial: NCT03472326
Drug: TAF
RxNorm normalized name: Altafed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet(s) administered orally once daily
Trial: NCT03472326
Drug: ARV regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARV regimen may consist of the ARV agents containing nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitor (NNRTI)
Trial: NCT03472326
Drug: DRV
RxNorm normalized name: Urinal Male Drv RTLPC23201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet(s) administered orally once daily
Trial: NCT03472326
Drug: RTV
RxNorm normalized name: Accu-Chek SmartView Test Strips
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet(s) administered orally once daily
Trial: NCT00990743
Drug: SYL040012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of single and multiple doses of SYL040012 in ophthalmic drops solution
Trial: NCT00683735
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mg 1-0-0-0
Trial: NCT00683735
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg 1-0-0-0
Trial: NCT00414206
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00307307
Drug: Niacin/simvastatin compared to simvastatin alone at 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03649165
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During Part 1 of the study, participants will receive single doses of selumetinib 25 mg granule under fasted conditions. The dose will be administered after an overnight fast of at least 10 hours. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose.
Trial: NCT03649165
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During Part 1 of the study, participants will receive single doses of selumetinib 50 mg capsule under fasted conditions. The dose will be administered after an overnight fast of at least 10 hours. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose.
Trial: NCT00369577
Drug: Inhaled Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Placebo, single dose
Trial: NCT03649165
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single 500mg dose of acetaminophen at the same time.
Trial: NCT02739035
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 weeks per mouth of celecoxib (200 mg daily)
Trial: NCT03394027
Drug: ONC201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 625 mg by mouth every 7 days; each cycle = 28 days. Patients will receive ONC201 as long as they derive clinical benefit or toxicity becomes impeditive.
Trial: NCT00940992
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application to face for 12 weeks
Trial: NCT01126307
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tid
Trial: NCT01985061
Drug: BX4-Suspended
RxNorm normalized name: SUSPENDING VEHICLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspended
Trial: NCT02083991
Drug: Steroid-free low TAC-arm: Thymoglobulin Standard low-TAC arm: Simulect, prednisolon
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03948334
Drug: ZPL389 30mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mg of ZPL389; once daily
Trial: NCT03948334
Drug: ZPL389 50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg of ZPL389; once daily
Trial: NCT03948334
Drug: TCS and/or TCI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids (TCS) and /or topical calcineurin inhibitors (TCI) were used concomitantly or intermittently based on disease severity.
Trial: NCT00298974
Drug: hydrocodone / acetaminophen extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets twice daily
Trial: NCT00298974
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets twice daily
Trial: NCT01547741
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01547741
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01884896
Drug: 'TOPROL-XL®' ER Tablets 200 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 \* 200 mg tablet per day
Trial: NCT04007263
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo via 30 minute infusion once daily for 5 days
Trial: NCT04007263
Drug: NP10679
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NP10679 25 mg via 30 minute infusion once daily for 5 days
Trial: NCT02292719
Drug: OBV/PTV/r
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT04171050
Drug: Local anaesthetic
RxNorm normalized name: Local anaesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthesia injections
Trial: NCT02220829
Drug: Standard Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of alpha-blocker Rapaflo only at onset of symptoms.
Trial: NCT02531724
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium chloride
Trial: NCT03663101
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A - 0.5 mL of sodium chloride solution 0.9% (saline solution) per injection point will be injected subcutaneously (maximum 10 injection points).
Trial: NCT00756418
Drug: Theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline 100 to 200 mg BID 4-weeks.
Trial: NCT03663101
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part B - 0.2 mL of sodium chloride solution 0.9% (saline solution) per injection point will be injected intradermally (maximum 10 injection points, 2,0 mL maximum).
Trial: NCT04346888
Drug: HBM9161 Injection (680mg and 340 mg)
RxNorm normalized name: INFLAMMATION AND INFECTION DETECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBM9161 Injection (680mg and 340mg)
Trial: NCT04346888
Drug: HBM9161 Injection (340 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBM9161 Injection (340 mg)
Trial: NCT02478099
Drug: MPDL3280A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-L1 antibody
Trial: NCT00837616
Drug: 17 B estradiol orally
RxNorm normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group A will be given estrogen by mouth daily(0.5 mg or 1mg or 2 mg of 17B Estradiol. Doses will vary depending on the blood levels of estrogen starting with the lower doses and adjusting these doses up as needed to keep the levels in the normal range. The estrogen will be taken for 21 days. In order to have a menstrual cycle progesterone will be given for 7 days, starting from day 14 through day 21 of each cycle. Then both medications are stopped on day 21 for a total of 7 days. Labs will be obtained at baseline, 1,2,3,6,9 and 12 months. Dual-energy X-ray absorptiometry (DXA) scan and calorimetry will be done at baseline and at 6 and 12 month.
Trial: NCT00837616
Drug: 17 B estradiol
RxNorm normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group B will be given estrogen via a patch applied to the skin twice a week (0.375mg or 0.05mg or 0.075mg) Doses will vary depending on the blood levels of estrogen starting with the lower doses and adjusting these doses up as needed to keep the levels in the normal range. The estrogen will be taken for 21 days. In order to have a menstrual cycle progesterone will be given for 7 days, starting from day 14 through day 21 of each cycle. Then both medications are stopped on day 21 for a total of 7 days. Labs will be obtained at baseline, 1,2,3,6,9 and 12 months. Dual-energy X-ray absorptiometry (DXA) scan and calorimetry will be done at baseline and at 6 and 12 month.
Trial: NCT03308708
Drug: Norepinephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine infusion (5miclml) is immediately started after spinal anesthesia. Rate starts at 30 ml/h and modified according to hemodynamic state
Trial: NCT02743013
Drug: CHF 5993 100/6/12,5 pMDI
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02743013
Drug: CHF 5993 100/6/12,5 DPI Test 1
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02743013
Drug: CHF 5993 100/6/12,5 DPI Test 2
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02743013
Drug: CHF 5993 100/6/12,5 pMDI replicate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04184297
Drug: Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)
RxNorm normalized name: Sinex Long-Acting Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: drug
Trial: NCT00385801
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02351180
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled steroid that may decrease airway inflammation and the risk of chronic rejection
Trial: NCT02351180
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will serve as a control treatment
Trial: NCT01171313
Drug: Placebo for Sinemet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed placebo for Sinemet
Trial: NCT00208767
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A matched placebo pill will be given orally daily.
Trial: NCT02163915
Drug: TAK-137 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-137 placebo-matching tablets
Trial: NCT01751724
Drug: Caffeine citrate
RxNorm normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enrolled subjects will be randomized to receive a study drug consisting of either blinded Caffeine citrate.~Randomization and study drug preparation will be done by the NICU pharmacy. Investigators and clinicians will be blinded to the assigned drug.~After randomization, an initial loading dose of 20 mg/Kg of study drug will be followed by a 5 mg/Kg/day maintenance dose. The assigned study drug will be administered intravenous or orally as determined by the clinical team.~Infants will continue to receive the study drug until 12 hours prior to the first elective extubation.